Centessa Pharmaceuticals plc
CNTA
$39.76
$0.060.15%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | 15.00M | 15.00M | 15.00M | 15.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | 15.00M | 15.00M | 15.00M | 15.00M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 0.00 | 15.00M | 15.00M | 15.00M | 15.00M |
| SG&A Expenses | 58.02M | 50.47M | 50.18M | 50.45M | 49.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 256.69M | 222.69M | 228.80M | 221.42M | 210.74M |
| Operating Income | -256.69M | -207.69M | -213.80M | -206.42M | -195.74M |
| Income Before Tax | -249.37M | -195.71M | -239.31M | -226.54M | -220.09M |
| Income Tax Expenses | 1.27M | 1.82M | 3.39M | 3.83M | 3.76M |
| Earnings from Continuing Operations | -250.64 | -197.53 | -242.70 | -230.37 | -223.85 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -250.64M | -197.53M | -242.70M | -230.37M | -223.85M |
| EBIT | -256.69M | -207.69M | -213.80M | -206.42M | -195.74M |
| EBITDA | -255.91M | -206.93M | -213.03M | -205.65M | -194.96M |
| EPS Basic | -1.77 | -1.45 | -1.83 | -1.78 | -1.81 |
| Normalized Basic EPS | -1.10 | -0.90 | -0.96 | -0.94 | -0.95 |
| EPS Diluted | -1.77 | -1.45 | -1.83 | -1.78 | -1.81 |
| Normalized Diluted EPS | -1.10 | -0.90 | -0.96 | -0.94 | -0.95 |
| Average Basic Shares Outstanding | 563.37M | 542.86M | 532.92M | 515.02M | 490.83M |
| Average Diluted Shares Outstanding | 563.37M | 542.86M | 532.92M | 515.02M | 490.83M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |